U.S. Markets close in 3 hrs 22 mins

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
17.48-0.01 (-0.06%)
As of 12:38PM EDT. Market open.
People also watch
MYLGILDNVSAMGNBMY
Full screen
Previous Close17.49
Open17.54
Bid17.50 x 2300
Ask17.51 x 700
Day's Range17.40 - 17.75
52 Week Range16.81 - 53.96
Volume6,907,574
Avg. Volume14,578,400
Market Cap17.75B
Beta0.51
PE Ratio (TTM)224.10
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.10 (6.44%)
Ex-Dividend Date2017-06-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Buy the Capitulation in Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock
    InvestorPlace3 hours ago

    Buy the Capitulation in Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock

    Don’t buy the pain meds Citi is prescribing in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). In our view, it’s too late to fill that order and this is a better occasion to take on a pick-me-up, contrarian position in TEVA with a bullish short-term options play. Apologies are a rare bird with analysts on Wall Street, and for that I almost want to tip the hat for Citi’s actions in TEVA stock.

  • Barrons.com3 hours ago

    Valeant: Hard to Ignore the Positive Developments?

    Shares of Valeant Pharmaceuticals International (VRX) have tumbled 14% in August as concerns about generic drugs following Teva Pharmaceutical Industries' (TEVA) earnings sparked a specialty-pharmaceutical stock selloff. Valeant, however, is trying to make back some of those losses this week, with the stock up more than 2% today after the company announced that it was close to fixing problems at a Bausch & Lomb plant. While this might seem like a minor piece of news, it has big implications for Valeant's stock.

  • Financial Times6 hours ago

    [$$] Generic drugmakers feel pinch as prices crumble

    If a company makes money by copying the inventions of others, is it entitled to skim a thick layer of cream off the top? That is the question on the lips of investors in generic drugmakers, after a torrid ...